23/03/2026
๐ง๐๐ผ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐๐ ๐บ๐ฎ๐ ๐ฟ๐ฒ๐ฐ๐ฒ๐ถ๐๐ฒ ๐๐ต๐ฒ ๐๐ฎ๐บ๐ฒ ๐บ๐ฒ๐ฑ๐ถ๐ฐ๐ฎ๐๐ถ๐ผ๐ป, ๐๐ฒ๐ ๐๐ต๐ฒ๐ถ๐ฟ ๐ผ๐๐๐ฐ๐ผ๐บ๐ฒ๐ ๐ฐ๐ฎ๐ป ๐ฏ๐ฒ ๐๐ฒ๐ฟ๐ ๐ฑ๐ถ๐ณ๐ณ๐ฒ๐ฟ๐ฒ๐ป๐.
One critical reason? Genetic variation.
Variants in the CYP2C19 gene can significantly affect how the body processes antiplatelet drugs like Clopidogrel. In some patients, the medication may not work as expected, increasing the risk of treatment failure.
Pharmacogenetic (PGx) testing helps identify these differences early, moving cardiology toward a more personalized approach.
๐ง๐ต๐ฒ ๐๐ป๐๐ฒ๐ป๐ฒ ๐ฃ๐น๐ฎ๐๐ณ๐ผ๐ฟ๐บ & ๐ฆ๐บ๐ฎ๐ฟ๐๐๐ฎ๐ฟ๐ฑ๐ถ๐ผ:
โข Efficient Analysis: The InGene Device enables rapid genetic testing in clinical settings.
โข Targeted Insights: The SmartCardio panel evaluates genetic variants specifically linked to cardiovascular drug response.
โข Informed Decisions: Helping clinicians choose the right treatment for the right patient, right from the start.
Discover how weโre advancing personalized cardiovascular care at SmartQR.